“In Canada, cancer immunotherapy for brain tumours is in early phases of development and requires proof-of-concept data. The support from Brain Cancer Canada fundraisers, donors, and philanthropists ...

Glioblastoma is the deadliest form of brain cancer, with less than a 5% five-year survival rate. One of the key contributors to glioblastoma’s poor outlook is its natural immunosuppression coupled ...